RHYTHM Biosciences Ltd - Asset Resilience Ratio

Latest as of December 2025: 2.74%

RHYTHM Biosciences Ltd (RHY) has an Asset Resilience Ratio of 2.74% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

AU$85.00K

≈ $60.14K USD Cash + Short-term Investments

Total Assets

AU$3.10 Million

≈ $2.19 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2018–2025)

This chart shows how RHYTHM Biosciences Ltd's Asset Resilience Ratio has changed over time. Check how strategically is RHYTHM Biosciences Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down RHYTHM Biosciences Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see RHYTHM Biosciences Ltd market cap and net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$0.00	0%
Short-term Investments	AU$85.00K	2.74%
Total Liquid Assets	AU$85.00K	2.74%

Asset Resilience Insights

Limited Liquidity: RHYTHM Biosciences Ltd maintains only 2.74% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

RHYTHM Biosciences Ltd Industry Peers by Asset Resilience Ratio

Compare RHYTHM Biosciences Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
LONZA GROUP UNSP.ADR 1/10 F:LO3A	Diagnostics & Research	3.04%
Dr. Lal Path Labs Ltd. NSE:LALPATHLAB	Diagnostics & Research	13.43%
BGI Genomics Co Ltd SHE:300676	Diagnostics & Research	3.62%
Fleury S.A. SA:FLRY3	Diagnostics & Research	16.06%
Centro de Imagem Diagnósticos S.A SA:AALR3	Diagnostics & Research	4.77%
Inoviq Ltd AU:IIQ	Diagnostics & Research	56.29%
Immunovia publ AB ST:IMMNOV	Diagnostics & Research	83.99%
GENINCODE PLC LS -01 F:9PL	Diagnostics & Research	1.54%

Annual Asset Resilience Ratio for RHYTHM Biosciences Ltd (2018–2025)

The table below shows the annual Asset Resilience Ratio data for RHYTHM Biosciences Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-06-30	3.00%	AU$85.00K ≈ $60.14K	AU$2.83 Million ≈ $2.00 Million	+0.04pp
2024-06-30	2.96%	AU$45.00K ≈ $31.84K	AU$1.52 Million ≈ $1.07 Million	+2.38pp
2023-06-30	0.58%	AU$45.00K ≈ $31.84K	AU$7.70 Million ≈ $5.45 Million	+0.05pp
2022-06-30	0.53%	AU$45.00K ≈ $31.84K	AU$8.44 Million ≈ $5.97 Million	-73.52pp
2021-06-30	74.06%	AU$2.27 Million ≈ $1.61 Million	AU$3.07 Million ≈ $2.17 Million	+4.40pp
2020-06-30	69.65%	AU$1.84 Million ≈ $1.30 Million	AU$2.65 Million ≈ $1.87 Million	-6.97pp
2019-06-30	76.63%	AU$4.77 Million ≈ $3.38 Million	AU$6.23 Million ≈ $4.41 Million	-16.00pp
2018-06-30	92.62%	AU$7.83 Million ≈ $5.54 Million	AU$8.45 Million ≈ $5.98 Million	--

pp = percentage points

About RHYTHM Biosciences Ltd

AU:RHY Australia Diagnostics & Research

Market Cap

$19.96 Million

AU$28.21 Million AUD

Market Cap Rank

#25090 Global

#1050 in Australia

Share Price

AU$0.09

Change (1 day)

-1.15%

52-Week Range

AU$0.05 - AU$0.26

All Time High

AU$2.00